Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

VATE - INNOVATE Corp. Latest News | Finranks

Home

VATE

I

INNOVATE Corp. (VATE)

NYQ – Real Time Price. Currency in USD

4.59

+0.56 (13.90%)

At close: Mar 27, 2026, 4:00 PM EDT

4.60

+0.01 (0.22%)

After-hours: Mar 27, 2026, 7:57 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

INNOVATE Corp. (VATE) Q4 2025 Earnings Call Prepared Remarks Transcript

INNOVATE Corp. (VATE) Q4 2025 Earnings Call Prepared Remarks Transcript

INNOVATE Corp. (VATE) Q4 2025 Earnings Call Prepared Remarks Transcript

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to deliver benefits beginning in 2026 -

INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th

INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2025 on Thursday, March 26, 2026, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor's Choice articles.1

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5 million, or $1.30 per share, on February 24, 2026 to DBMG's stockholders of record at the close of business on February 9, 2026. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $4.6 million of the total $5 million dividend payout. INNOVATE's individual stockholders are not eligible to receive the cash dividend.

MediBeacon® Next Generation TGFR™ System Receives FDA Approval

MediBeacon® Next Generation TGFR™ System Receives FDA Approval

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, has received approval from the U.S. Food and Drug Administration (FDA) for the next generation MediBeacon® TGFRTM System including the latest TGFRTM Reusable Sensor.

INNOVATE Corp. (VATE) Q3 2025 Earnings Call Transcript

INNOVATE Corp. (VATE) Q3 2025 Earnings Call Transcript

INNOVATE Corp. ( VATE ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Neel Sikka Paul Voigt - Interim Chief Executive Officer Michael Sena - CFO, Treasurer & Corporate Secretary Presentation Operator Good afternoon, and welcome to the INNOVATE Corp Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Videos

No Data

There is no data to display

Press releases

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to deliver benefits beginning in 2026 -

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor's Choice articles.1

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated steel construction services, and an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5 million, or $1.30 per share, on February 24, 2026 to DBMG's stockholders of record at the close of business on February 9, 2026. As the largest stockholder of DBMG, INNOVATE expects to receive approximately $4.6 million of the total $5 million dividend payout. INNOVATE's individual stockholders are not eligible to receive the cash dividend.

MediBeacon® Next Generation TGFR™ System Receives FDA Approval

MediBeacon® Next Generation TGFR™ System Receives FDA Approval

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, has received approval from the U.S. Food and Drug Administration (FDA) for the next generation MediBeacon® TGFRTM System including the latest TGFRTM Reusable Sensor.